← Leaderboards
Nicholas Elwood Johnson
Virginia Commonwealth University
$13,044,511
Attributed
$14,906,264
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,420,352 · 7
FDA$3,271,152 · 1
CDC$2,709,536 · 2
By mechanism
R01$7,131,965 · 2
U01$5,726,870 · 3
P50$2,092,686 · 3
K23$997,164 · 1
R21$452,355 · 1
Top collaborators
- Charles A Thornton6 shared
- Jeffrey Statland2 shared
- John A Berglund1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- John T. Povlishock$16,843,993
- Jose Francisco Huizar$2,594,731
- Julia Marie Hartman$45,988
- Denielle M Perry$191,167
Others in their field
Top investigators on “Therapeutic Trials”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$388,668,383
- Judith S. Currier · University Of California Los Angeles$364,946,020
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
Research focus
Therapeutic TrialsGenesMuscleMotorFutureMuscle FunctionBiological MarkersCohortDisease ProgressionSymptomsAffectRna SplicingMyotonic DystrophyEnrollmentBiologicalTherapeutic DevelopmentPatternCongenital Myotonic DystrophyResearch PersonnelChildhoodChildPathogenesisAdultMuscular Dystrophies
Grant awards (34)
Preparing for Therapeutics across the Spectrum of Myotonic Dystrophy$1,494,776
P50 · FY2025 · AR · contact PI
Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1)$933,443
U01 · FY2025 · NS · contact PI
Identifying the RNA Splicing and Gene Expression Changes that Cause Congenital Myotonic Dystrophy (Renewal)$600,108
R01 · FY2025 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)$398,302
R01 · FY2025 · FD · contact PI
Genome Wide Association Study$298,955
P50 · FY2025 · AR · contact PI
Pediatric Natural History$298,955
P50 · FY2025 · AR · contact PI
Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1)$944,850
U01 · FY2024 · NS · contact PI
Identifying the RNA Splicing and Gene Expression Changes that Cause Congenital Myotonic Dystrophy (Renewal)$619,566
R01 · FY2024 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)$399,847
R01 · FY2024 · FD · contact PI
Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1)$1,139,041
U01 · FY2023 · NS · contact PI
Network for Observational Study of Virginia Muscular Dystrophies (NoVA MD)$400,000
U01 · FY2023 · DD · contact PI
Identifying the RNA Splicing and Gene Expression Changes that cause Congenital Myotonic Dystrophy$497,138
R01 · FY2022 · NS · contact PI
Network for Observational Study of Virginia Muscular Dystrophies (NoVA MD)$395,000
U01 · FY2022 · DD · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)$386,995
R01 · FY2022 · FD · contact PI
Identifying the RNA Splicing and Gene Expression Changes that cause Congenital Myotonic Dystrophy$526,200
R01 · FY2021 · NS · contact PI
Network for Observational Study of Virginia Muscular Dystrophies (NoVA MD)$342,314
U01 · FY2021 · DD · contact PI
Development and validation of clinical outcome assessments in LGMD2A$198,181
R21 · FY2021 · TR · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1$98,005
R01 · FY2021 · FD · contact PI
Identifying the RNA Splicing and Gene Expression Changes that cause Congenital Myotonic Dystrophy$535,806
R01 · FY2020 · NS · contact PI
Network for Observational Study of Virginia Muscular Dystrophies (NoVA MD)$348,540
U01 · FY2020 · DD · contact PI
Development and validation of clinical outcome assessments in LGMD2A$254,174
R21 · FY2020 · TR · contact PI
Identifying the RNA Splicing and Gene Expression Changes that cause Congenital Myotonic Dystrophy$535,657
R01 · FY2019 · NS · contact PI
Network for Observational Study of Virginia Muscular Dystrophies (NoVA MD)$348,689
U01 · FY2019 · DD · contact PI
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)$203,040
K23 · FY2019 · NS · contact PI
Identifying the RNA Splicing and Gene Expression Changes that cause Congenital Myotonic Dystrophy$546,338
R01 · FY2018 · NS · contact PI
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)$151,938
K23 · FY2018 · NS · contact PI
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)$51,102
K23 · FY2018 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1$1,961,707
R01 · FY2017 · FD · contact PI
Comp B-Western Intermountain Regional NMD STARnet$449,993
U01 · FY2017 · DD · contact PI
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)$201,960
K23 · FY2017 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1$26,296
R01 · FY2017 · FD · contact PI
Comp B-Western Intermountain Regional NMD STARnet$425,000
U01 · FY2016 · DD · contact PI
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)$194,562
K23 · FY2016 · NS · contact PI
Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)$194,562
K23 · FY2015 · NS · contact PI